ipm514
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2024 (NCT06690476)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07203898 | Phase 1 | Jun 30, 2026 | Beijing Immupeutics Medicine Technology Limited |
| NCT06690476 | Early Phase 1 (Phase 1) | Oct 10, 2024 | Peking University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Immupeutics Medicine Technology Limited | For profit | 1 | 1 | 1 | 2026 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1